S&P 500   4,277.00 (+0.08%)
DOW   33,500.58 (-0.19%)
QQQ   354.40 (-0.14%)
AAPL   179.25 (-0.18%)
MSFT   333.07 (-0.85%)
META   272.23 (+0.31%)
GOOGL   127.47 (+1.16%)
AMZN   126.37 (+0.85%)
TSLA   219.67 (+0.95%)
NVDA   384.38 (-1.87%)
NIO   7.84 (+2.22%)
BABA   86.69 (+2.71%)
AMD   121.92 (+3.38%)
T   15.63 (+1.56%)
F   12.86 (+2.14%)
MU   67.38 (-0.58%)
CGC   0.74 (-5.01%)
GE   105.10 (+0.96%)
DIS   92.04 (+1.14%)
AMC   4.63 (+0.00%)
PFE   38.46 (-0.49%)
PYPL   64.79 (+0.43%)
NFLX   398.43 (-1.27%)
S&P 500   4,277.00 (+0.08%)
DOW   33,500.58 (-0.19%)
QQQ   354.40 (-0.14%)
AAPL   179.25 (-0.18%)
MSFT   333.07 (-0.85%)
META   272.23 (+0.31%)
GOOGL   127.47 (+1.16%)
AMZN   126.37 (+0.85%)
TSLA   219.67 (+0.95%)
NVDA   384.38 (-1.87%)
NIO   7.84 (+2.22%)
BABA   86.69 (+2.71%)
AMD   121.92 (+3.38%)
T   15.63 (+1.56%)
F   12.86 (+2.14%)
MU   67.38 (-0.58%)
CGC   0.74 (-5.01%)
GE   105.10 (+0.96%)
DIS   92.04 (+1.14%)
AMC   4.63 (+0.00%)
PFE   38.46 (-0.49%)
PYPL   64.79 (+0.43%)
NFLX   398.43 (-1.27%)
S&P 500   4,277.00 (+0.08%)
DOW   33,500.58 (-0.19%)
QQQ   354.40 (-0.14%)
AAPL   179.25 (-0.18%)
MSFT   333.07 (-0.85%)
META   272.23 (+0.31%)
GOOGL   127.47 (+1.16%)
AMZN   126.37 (+0.85%)
TSLA   219.67 (+0.95%)
NVDA   384.38 (-1.87%)
NIO   7.84 (+2.22%)
BABA   86.69 (+2.71%)
AMD   121.92 (+3.38%)
T   15.63 (+1.56%)
F   12.86 (+2.14%)
MU   67.38 (-0.58%)
CGC   0.74 (-5.01%)
GE   105.10 (+0.96%)
DIS   92.04 (+1.14%)
AMC   4.63 (+0.00%)
PFE   38.46 (-0.49%)
PYPL   64.79 (+0.43%)
NFLX   398.43 (-1.27%)
S&P 500   4,277.00 (+0.08%)
DOW   33,500.58 (-0.19%)
QQQ   354.40 (-0.14%)
AAPL   179.25 (-0.18%)
MSFT   333.07 (-0.85%)
META   272.23 (+0.31%)
GOOGL   127.47 (+1.16%)
AMZN   126.37 (+0.85%)
TSLA   219.67 (+0.95%)
NVDA   384.38 (-1.87%)
NIO   7.84 (+2.22%)
BABA   86.69 (+2.71%)
AMD   121.92 (+3.38%)
T   15.63 (+1.56%)
F   12.86 (+2.14%)
MU   67.38 (-0.58%)
CGC   0.74 (-5.01%)
GE   105.10 (+0.96%)
DIS   92.04 (+1.14%)
AMC   4.63 (+0.00%)
PFE   38.46 (-0.49%)
PYPL   64.79 (+0.43%)
NFLX   398.43 (-1.27%)
NASDAQ:REPL

Replimune Group (REPL) Stock Forecast, Price & News

$24.37
+1.77 (+7.83%)
(As of 02:26 PM ET)
Compare
Today's Range
$22.32
$24.69
50-Day Range
$15.65
$22.60
52-Week Range
$13.84
$29.52
Volume
647,776 shs
Average Volume
551,116 shs
Market Capitalization
$1.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.60

Replimune Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.2% Upside
$51.80 Price Target
Short Interest
Bearish
17.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.59mentions of Replimune Group in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$1 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.57) to ($3.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

362nd out of 984 stocks

Biological Products, Except Diagnostic Industry

53rd out of 160 stocks


REPL stock logo

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
EF Hutton Remains a Buy on Replimune Group (REPL)
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
BMO Capital Keeps Their Buy Rating on Replimune Group (REPL)
Recap: Replimune Group Q4 Earnings
See More Headlines

REPL Price History

REPL Company Calendar

Last Earnings
11/04/2021
Today
6/06/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
152
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$51.80
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+128.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-174,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.80 per share

Miscellaneous

Free Float
44,025,000
Market Cap
$1.31 billion
Optionable
Not Optionable
Beta
1.64

Key Executives

  • Philip Astley-Sparke
    Chief Executive Officer & Director
  • Robert CoffinRobert Coffin
    President & Director
  • Colin A. LoveColin A. Love
    Chief Operating Officer
  • Jean M. Franchi
    Chief Financial Officer, Secretary & Treasurer
  • Konstantinos Xynos
    Chief Medical Officer













REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price forecast for 2023?

5 equities research analysts have issued 1-year price targets for Replimune Group's stock. Their REPL share price forecasts range from $34.00 to $70.00. On average, they anticipate the company's stock price to reach $51.80 in the next twelve months. This suggests a possible upside of 129.2% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2023?

Replimune Group's stock was trading at $27.20 at the beginning of 2023. Since then, REPL stock has decreased by 16.9% and is now trading at $22.60.
View the best growth stocks for 2023 here
.

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our REPL earnings forecast
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.05.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.70%), BlackRock Inc. (6.39%), State Street Corp (5.13%), BVF Inc. IL (3.78%), FMR LLC (2.04%) and Dimensional Fund Advisors LP (1.90%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke, Robert Coffin and Sushil Patel.
View institutional ownership trends
.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $22.60.

How much money does Replimune Group make?

Replimune Group (NASDAQ:REPL) has a market capitalization of $1.31 billion. The company earns $-174,280,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does Replimune Group have?

The company employs 152 workers across the globe.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -